SAN DIEGO & SINGAPORE–(BUSINESS WIRE)–ImmunoScape, a biotechnology company focused on next-generation T Cell receptor (TCR)-based immunotherapies, today announced that three abstracts have been accepted for poster presentations at the 2024 American...
ImmunoScape Leadership to Present at Upcoming Industry Conferences CEO Choon-Peng Ng and Vice President of Innovation, Michael Fehlings, Ph.D., will discuss Asia’s role in the “golden age” of biotech and AI in therapeutics SAN DIEGO, Calif., and Singapore – March 1,...
2023 was an exciting year at ImmunoScape, featuring transformative technical progress, new partnerships, expert additions to our leadership team and more. Read our latest newsletter for a look back at the highlights as well as a look ahead at what’s on the way for...
The collaboration seeks to produce novel off-the-shelf TCR-based bispecific molecules designed to overcome current limitations in cell therapy approaches against solid tumors SAN DIEGO, Calif., and Singapore – December 21, 2023 – ImmunoScape, a biotechnology...
MiNK Therapeutics combines its unique, proprietary library of T-cell antigens with ImmunoScape’s cutting-edge platform for rapid discovery of novel T-cell receptors Therapeutic development to focus on novel cell therapies as well as bispecific immune cell...